Sanofi: approval for esophagitis in children
This approval is based on the results of the Phase III EoE KIDS trial, which showed that a greater proportion of children treated with Dupixent achieved histological remission compared to placebo.
This approval extends the one granted by the FDA in May 2022 for patients aged 12 and over and weighing at least 40 kg. Eosinophilic esophagitis is the fifth indication modulated by underlying type 2 inflammation to be approved for Dupixent in the U.S.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction